查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1495993

C 反应蛋白 (CRP) 检测的全球市场：2024-2029 年预测

Global C-Reactive Protein (CRP) Testing Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 124 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

C反应蛋白（CRP）检测市场预计到2022年将达到19.53亿美元，预测期内复合年增长率为2.43%，预计到2029年市场总规模将达到22.93亿美元。

CRP测试是测量体内CRP浓度的测试。体内 C 反应蛋白水平升高是由发炎引起的。这种蛋白质是在肝臟产生的。使用 C 反应蛋白检测来识别和追踪发炎疾病和感染疾病。 C反应蛋白测试包括癌症、心血管疾病、关节炎等。此测试可评估您是否有心臟病发作或中风的风险。

心血管疾病（CVD）变得越来越普遍，检测也变得越来越复杂，因此这个市场正受到这些因素的推动。根据世界卫生组织的报告，CVD 每年导致约 1,790 万人死亡。这个市场有很多机会，包括扩大这些测试的应用、就地检验、增加人口覆盖率以及提高医疗保健意识，特别是在开发中国家。

由于政府向学术研究机构和个人提供的资金增加，预计该市场也会成长。此外，世界卫生组织和美国国立卫生研究院等国际组织旨在预防和治疗癌症和心血管疾病等慢性疾病的各种措施也有望推动市场成长。

在全球范围内，由于发炎疾病盛行率的上升、女性子宫内膜异位症盛行率的增加以及诊断检测技术的进步，C反应蛋白检测市场将会成长。许多慢性疾病，包括狼疮、溃疡性大肠炎和类风湿性关节炎，被认为是由慢性发炎引发的。

根据美国疾病管制与预防中心 (CDC) 2016 年的报告，预计到 2040 年，大约 7,800 万 (26%) 18 岁及以上的美国成年人将患有关节炎。此外，该市场的成长也因缺乏公众意识而受到挑战。

市场驱动因素：

  • 心血管疾病的增加预计将推动 C 反应蛋白 (CRP) 检测市场的成长。

鑑于心血管疾病的高盛行率，迫切需要开发快速、准确的诊断方法。因此，CRP 可用于检测由于动脉粥状硬化的发展而导致的 CVD，其中胆固醇沉积在血管壁内并引起发炎。因此，心血管疾病患者的 CRP 水平较高。

因此，这些 CRP检测法可以高灵敏度检测低 CRP 水平。随着心血管疾病变得越来越普遍，研究人员可能会继续评估 CRP 对心血管疾病的影响。据世界心臟联合会称，心臟疾病是全世界死亡的主要原因。据估计，每年有380万名男性和340万名女性死于心臟疾病。 80%以上的死亡发生在低收入和中等收入国家。

此外，根据美国心臟协会 2019 年的资料，美国每年约有 356,000 例院外心臟麻痹，其中 90% 是致命的。这就是临床医生越来越多地进行 CRP 检测的原因。因此，这些因素共同导致心血管疾病领域在预测期内稳定成长。

许多研究和开发计划是由大学和其他组织进行的。例如，香港大学的研究小组开发了一种即时、灵活的感测装置，可以直接测量CRP血液水平。使用该感测器，发炎测试速度比正常情况快 30 倍。此类事件是促进 CRP 检测市场成长的主要因素。

  • 定期 CRP 测试的技术改进预计将推动市场成长。

随着时间的推移，CRP 已发展成为一种用于确定全身发炎疾病的灵活诊断工具。奈米材料和电分析化学的进步导致了具有更高灵敏度和特异性的 CRP 测试的创建。 CRP 测试已发展为使用现代电化学生物感测器的基于 CRP 的酵素测试，并逐渐取代经典的抗原抗体交互作用。

基于ZnS奈米颗粒、金属氧化物半导体场效电晶体/双极电晶体、适配体、硅奈米线、垂直流免疫免疫检测、场发射发射器和其他奈米材料的电化学感测器具有高灵敏度和可携式，用于检测的开发。

多学科方法的未来进步应该能够在更短的时间内实现超灵敏的 CRP 水平分析。因此，用于诊断全身发炎疾病的CRP检测方法可能会被更多人使用。有助于创建感测平台的新 CRP 识别化学物质和材料也为 CRP 测试市场提供了许多前景。

市场限制因素：

  • 高成本和低社会意识可能会阻碍市场成长。

然而，CRP检测设备价格昂贵。高成本在指定对市场起到限製作用。此外，该领域合格专业人员的缺乏也会在一定时期内阻碍CRP检测市场的发展。此外，大众对 CRP 检测的认识较低以及诊断某些疾病的特异性较低预计也会抑制市场成长。

主要进展

  • 2022 年 11 月 - ProciseDx 的 ProciseDx 装置和 C 反应蛋白 (CRP)检测法可在 5 分钟内定量测量患者血清中的 CRP 浓度。该公司还预计 FDA 会批准其他测试。 ProciseDx 已获得 CE 标誌，并在欧洲启动了四项消化器官系统测试，已安装 30 台机器，50 个设施正准备实施。在美国，ProciseDx 提交了测量两项 TDM 测试的从头申请，Procise IFX 测量Infliximab（Remicade和生物仿製药），Procise ADL 测量Adalimumab（Humira和生物仿製药）。
  • 2022 年 1 月 - LumiraDx 是下一代照护现场，获得 C 反应蛋白 (CRP) 测试的 CE 标誌。该测试是一种小型、便携式、全自动微流体免疫检测，可在 4 分钟内定量测量 CRP。此测试有助于检测和评估感染疾病和发炎，CRP水平高表明有呼吸道感染疾病症状的患者需要抗生素治疗，而CRP水平正常或低值表明感染疾病或自限性感染疾病，不需要抗生素。它可以在基层医疗、社区护理、患者家中和医院急诊护理中靠近患者使用。

目录

第一章简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关利益者的主要利益

第二章调查方法

  • 研究设计
  • 调查过程

第三章执行摘要

  • 主要发现

第四章市场动态

  • 市场驱动因素
  • 市场限制因素
  • 波特五力分析
  • 产业价值链分析
  • 分析师观点

第五章全球 C 反应蛋白 (CRP) 测试市场：按类型

  • 介绍
  • 免疫比浊法
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • ELISA
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 化学冷光
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 光谱分析
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力

第六章 C 反应蛋白 (CRP) 测试的全球市场：按应用分类

  • 介绍
  • 心血管疾病
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 癌症
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 类风湿性关节炎
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 狼疮
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 其他的
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力

第七章 全球 C 反应蛋白 (CRP) 测试市场：依最终用户分类

  • 介绍
  • 医院和诊所
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 诊断中心
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力

第八章全球C反应蛋白（CRP）检测市场：按地区

  • 介绍
  • 北美洲
    • 按类型
    • 按用途
    • 按最终用户
    • 按国家/地区
  • 南美洲
    • 按类型
    • 按用途
    • 按最终用户
    • 按国家/地区
  • 欧洲
    • 按类型
    • 按用途
    • 按最终用户
    • 按国家/地区
  • 中东/非洲
    • 按类型
    • 按用途
    • 按最终用户
    • 按国家/地区
  • 亚太地区
    • 按类型
    • 按用途
    • 按最终用户
    • 按国家/地区

第九章竞争环境及分析

  • 主要企业及策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作
  • 竞争对手仪表板

第十章 公司简介

  • Medix Biochemica
  • Biolab
  • Abbott
  • Novus Biologicals, LLC
  • Cenogenics Corporation
  • Salimetrics, LLC
  • Randox Laboratories Ltd
  • Thermo Fisher Scientific
  • Beckman Coulter, Inc.
  • Trinity Biotech
简介目录
Product Code: KSI061611697

The C-Reactive Protein (CRP) testing market was valued at US$1.953 billion in 2022 and is expected to grow at a CAGR of 2.43% over the forecast period to reach a total market size of US$2.293 billion by 2029.

Tests for C-reactive protein (CRP) measure levels of this protein in the body. An increase in C-reactive protein levels in the body can be attributed to inflammation. The liver produces this protein. Inflammatory diseases and infections are identified and tracked by C-reactive protein tests, which include cancers, cardiovascular disease, arthritis, etc. The tests estimate whether someone is at risk of having a heart attack or stroke.

Cardiovascular diseases (CVDs) have become more prevalent, and as tests are becoming more complex, this market is being driven by these factors. As reported by the WHO, CVDs kill about 17.9 million people each year. Numerous opportunities exist in the market, including the growing application of these tests, point-of-care testing, increased population coverage, and increased healthcare awareness, particularly in developing countries.

The market is also expected to grow due to increased funds provided by the government to academic research institutions and individuals. Market growth is further anticipated to be supported by various initiatives by international organizations, including WHO and NIH, that aim to prevent and treat chronic disorders such as cancer and cardiovascular diseases.

Globally, the market for C-reactive protein tests will grow because of the rising prevalence of inflammatory disorders, the increasing prevalence of endometriosis in women, and technological advancements in diagnostic tests. A large number of chronic diseases, including lupus, ulcerative colitis, rheumatoid arthritis, and others, are thought to be triggered by chronic inflammation.

According to the Centers for Disease Control and Prevention (CDC) 2016 report, it is estimated that by 2040, approximately 78 million (26%) of US adults aged 18 and up will have arthritis. Furthermore, this market's growth would be challenged by the lack of public awareness.

Market Drivers:

  • An increase in cardiovascular disease is anticipated to surge the C-reactive protein (CRP) testing market growth.

It is urgently necessary to develop a quick and accurate method for diagnosing cardiovascular diseases, given their high prevalence. CRP can, therefore, be used to detect CVD due to the development of atherosclerosis, in which cholesterol is deposited inside blood vessel walls, leading to inflammation. As a result, CRP levels are higher in patients with cardiovascular disease.

Consequently, these CRP assays can detect low CRP levels, which are sensitive. Because cardiovascular diseases are increasingly prevalent, researchers are likely to pursue evaluations of CRP for cardiovascular disorders. According to the World Heart Federation, coronary heart disease is the leading cause of death in the world. There are an estimated 3.8 million males and 3.4 million females who die of coronary heart disease every year. More than 80% of deaths occur in low- and middle-income countries.

Additionally, approximately 356,000 cardiac arrests occur in the U.S. outside of hospitals every year, of which 90% are fatal, according to data from the American Heart Association 2019. It is for this reason that clinicians are increasingly implementing CRP testing. Hence, these factors combined are causing the cardiovascular diseases segment to grow at a steady pace over the forecast period.

Many research and development projects are conducted by universities and other organizations. For example, a group of researchers from the University of Hong Kong has developed a real-time, flexible sensing device that can directly measure CRP blood levels. With this sensor, inflammation testing is 30 times faster than usual. Incidents such as these are a major factor contributing to the C-reactive protein testing market growth.

  • Technological improvements in regular CRP tests are expected to propel the market growth.

Over time, CRP has developed into a flexible diagnostic tool for determining systemic inflammatory disorders. Advances in nanomaterials and electroanalytical chemistry have led to the creation of CRP tests with higher sensitivity and specificity. CRP testing has advanced to include CRP-based enzymatic tests using modern electrochemical biosensors, gradually replacing classical antigen-antibody interactions.

Electrochemical sensors are used in the development of a highly sensitive, portable detection system based on ZnS nanoparticles, metal-oxide-semiconductor field-effect transistor/bipolar junction transistor, aptamer, silicon nanowire, vertical flow immunoassay, field emission transmitter, and other nanomaterials.

Ultrasensitive CRP level analysis should be possible in much less time with future advancements in multidisciplinary approaches. Thus, CRP testing methods for diagnosing systemic inflammatory illnesses would be used by more individuals. New CRP identification chemicals and materials that facilitate the creation of sensing platforms also present a lot of prospects in the CRP testing market.

Market Restraints:

  • High cost and low public awareness could hinder market growth.

CRP testing instruments, however, are expensive. High costs will constrain the market during the given period. The lack of qualified professionals in the field will also hinder the market for CRP tests during the given period. In addition, low public awareness about the CRP test, as well as its low specificity in diagnosing a particular disease, are expected to restrain the market's growth.

Key Developments:

  • November 2022- ProciseDx received FDA clearance for its ProciseDx instrument and C Reactive Protein (CRP) assay, which provides quantitative determination of CRP levels in patient serum in less than 5 minutes. The company expects FDA clearances for additional tests. ProciseDx has already obtained CE Marks and launched four gastroenterology tests in Europe, with 30 instruments installed and 50 sites working towards implementation. In the US, ProciseDx has submitted De Novo applications for two TDM tests, Procise IFX measures infliximab (Remicade(R) and biosimilars), and Procise ADL measures adalimumab (Humira(R) and biosimilars).
  • January 2022- LumiraDx, a next-generation point-of-care diagnostics company, achieved CE Marking for its C-reactive protein (CRP) Test. The test is a small, portable, fully automated microfluidic immunoassay that provides quantitative CRP determination within four minutes. It helps detect and evaluate infection and inflammation, with high CRP levels indicating antibiotic treatment in patients with respiratory infection symptoms, while normal or low CRP levels indicate viral or self-limiting infections that don't require antibiotics. It can be used at the patient's side in primary and community care, patient homes, and hospital emergency care settings.

Market Segmentation:

By Type

  • Immunoturbidimetric method
  • ELISA
  • Chemiluminescence
  • Spectrometry

By Application

  • Cardiovascular Diseases
  • Cancer
  • Rheumatoid Arthritis
  • Lupus
  • Others

By End Users

  • Hospitals and Clinics
  • Diagnostic Centres

By Geography

  • North America
  • United States
  • Canada
  • Others
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • China
  • India
  • South Korea
  • Taiwan
  • Thailand
  • Indonesia
  • Japan
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. GLOBAL C-REACTIVE PROTEIN (CRP) TESTING MARKET BY TYPE

  • 5.1. Introduction
  • 5.2. Immunoturbidimetric method
    • 5.2.1. Market Opportunities and Trends
    • 5.2.2. Growth Prospects
    • 5.2.3. Geographic Lucrativeness
  • 5.3. ELISA
    • 5.3.1. Market Opportunities and Trends
    • 5.3.2. Growth Prospects
    • 5.3.3. Geographic Lucrativeness
  • 5.4. Chemiluminescence
    • 5.4.1. Market Opportunities and Trends
    • 5.4.2. Growth Prospects
    • 5.4.3. Geographic Lucrativeness
  • 5.5. Spectrometry
    • 5.5.1. Market Opportunities and Trends
    • 5.5.2. Growth Prospects
    • 5.5.3. Geographic Lucrativeness

6. GLOBAL C-REACTIVE PROTEIN (CRP) TESTING MARKET BY APPLICATION

  • 6.1. Introduction
  • 6.2. Cardiovascular Diseases
    • 6.2.1. Market Opportunities and Trends
    • 6.2.2. Growth Prospects
    • 6.2.3. Geographic Lucrativeness
  • 6.3. Cancer
    • 6.3.1. Market Opportunities and Trends
    • 6.3.2. Growth Prospects
    • 6.3.3. Geographic Lucrativeness
  • 6.4. Rheumatoid Arthritis
    • 6.4.1. Market Opportunities and Trends
    • 6.4.2. Growth Prospects
    • 6.4.3. Geographic Lucrativeness
  • 6.5. Lupus
    • 6.5.1. Market Opportunities and Trends
    • 6.5.2. Growth Prospects
    • 6.5.3. Geographic Lucrativeness
  • 6.6. Others
    • 6.6.1. Market Opportunities and Trends
    • 6.6.2. Growth Prospects
    • 6.6.3. Geographic Lucrativeness

7. GLOBAL C-REACTIVE PROTEIN (CRP) TESTING MARKET BY END USERS

  • 7.1. Introduction
  • 7.2. Hospitals and Clinics
    • 7.2.1. Market Opportunities and Trends
    • 7.2.2. Growth Prospects
    • 7.2.3. Geographic Lucrativeness
  • 7.3. Diagnostic Centres
    • 7.3.1. Market Opportunities and Trends
    • 7.3.2. Growth Prospects
    • 7.3.3. Geographic Lucrativeness

8. GLOBAL C-REACTIVE PROTEIN (CRP) TESTING MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. By Type
    • 8.2.2. By Application
    • 8.2.3. By End Users
    • 8.2.4. By Country
      • 8.2.4.1. United States
        • 8.2.4.1.1. Market Opportunities and Trends
        • 8.2.4.1.2. Growth Prospects
      • 8.2.4.2. Canada
        • 8.2.4.2.1. Market Opportunities and Trends
        • 8.2.4.2.2. Growth Prospects
      • 8.2.4.3. Mexico
        • 8.2.4.3.1. Market Opportunities and Trends
        • 8.2.4.3.2. Growth Prospects
  • 8.3. South America
    • 8.3.1. By Type
    • 8.3.2. By Application
    • 8.3.3. By End Users
    • 8.3.4. By Country
      • 8.3.4.1. Brazil
        • 8.3.4.1.1. Market Opportunities and Trends
        • 8.3.4.1.2. Growth Prospects
      • 8.3.4.2. Argentina
        • 8.3.4.2.1. Market Opportunities and Trends
        • 8.3.4.2.2. Growth Prospects
      • 8.3.4.3. Others
        • 8.3.4.3.1. Market Opportunities and Trends
        • 8.3.4.3.2. Growth Prospects
  • 8.4. Europe
    • 8.4.1. By Type
    • 8.4.2. By Application
    • 8.4.3. By End Users
    • 8.4.4. By Country
      • 8.4.4.1. United Kingdom
        • 8.4.4.1.1. Market Opportunities and Trends
        • 8.4.4.1.2. Growth Prospects
      • 8.4.4.2. Germany
        • 8.4.4.2.1. Market Opportunities and Trends
        • 8.4.4.2.2. Growth Prospects
      • 8.4.4.3. France
        • 8.4.4.3.1. Market Opportunities and Trends
        • 8.4.4.3.2. Growth Prospects
      • 8.4.4.4. Others
        • 8.4.4.4.1. Market Opportunities and Trends
        • 8.4.4.4.2. Growth Prospects
  • 8.5. Middle East and Africa
    • 8.5.1. By Type
    • 8.5.2. By Application
    • 8.5.3. By End Users
    • 8.5.4. By Country
      • 8.5.4.1. Saudi Arabia
        • 8.5.4.1.1. Market Opportunities and Trends
        • 8.5.4.1.2. Growth Prospects
      • 8.5.4.2. UAE
        • 8.5.4.2.1. Market Opportunities and Trends
        • 8.5.4.2.2. Growth Prospects
      • 8.5.4.3. Israel
        • 8.5.4.3.1. Market Opportunities and Trends
        • 8.5.4.3.2. Growth Prospects
      • 8.5.4.4. Others
        • 8.5.4.4.1. Market Opportunities and Trends
        • 8.5.4.4.2. Growth Prospects
  • 8.6. Asia Pacific
    • 8.6.1. By Type
    • 8.6.2. By Application
    • 8.6.3. By End Users
    • 8.6.4. By Country
      • 8.6.4.1. China
        • 8.6.4.1.1. Market Opportunities and Trends
        • 8.6.4.1.2. Growth Prospects
      • 8.6.4.2. India
        • 8.6.4.2.1. Market Opportunities and Trends
        • 8.6.4.2.2. Growth Prospects
      • 8.6.4.3. South Korea
        • 8.6.4.3.1. Market Opportunities and Trends
        • 8.6.4.3.2. Growth Prospects
      • 8.6.4.4. Taiwan
        • 8.6.4.4.1. Market Opportunities and Trends
        • 8.6.4.4.2. Growth Prospects
      • 8.6.4.5. Thailand
        • 8.6.4.5.1. Market Opportunities and Trends
        • 8.6.4.5.2. Growth Prospects
      • 8.6.4.6. Indonesia
        • 8.6.4.6.1. Market Opportunities and Trends
        • 8.6.4.6.2. Growth Prospects
      • 8.6.4.7. Japan
        • 8.6.4.7.1. Market Opportunities and Trends
        • 8.6.4.7.2. Growth Prospects
      • 8.6.4.8. Others
        • 8.6.4.8.1. Market Opportunities and Trends
        • 8.6.4.8.2. Growth Prospects

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Medix Biochemica
  • 10.2. Biolab
  • 10.3. Abbott
  • 10.4. Novus Biologicals, LLC
  • 10.5. Cenogenics Corporation
  • 10.6. Salimetrics, LLC
  • 10.7. Randox Laboratories Ltd
  • 10.8. Thermo Fisher Scientific
  • 10.9. Beckman Coulter, Inc.
  • 10.10. Trinity Biotech